JPWO2019230957A1 - Composition for promoting muscle repair - Google Patents

Abstract

An object of the present invention is to provide a novel composition for promoting muscle repair. By using bacterial cells belonging to Lactobacillus and / or a culture thereof as an active ingredient, it becomes possible to provide foods and drinks and feeds having a muscle repair promoting action.

Description

The present invention relates to a composition for promoting muscle repair.

Skeletal muscle is the largest organ that occupies about 40% of human body weight, and its functions are diverse, such as posture maintenance, energy metabolism, and protection of internal organs, in addition to whole body exercise.

Skeletal muscle has a repair function, and when it is physically or chemically damaged, the damaged site is repaired by the action of muscle satellite cells located around the muscle fibers. Myosatellite cells are usually quiescent, but when skeletal muscle is damaged, they become activated and differentiate into myoblasts. After proliferation, myoblasts differentiate into myotubes and fuse with the injured site to repair skeletal muscle.

Granulocyte colony stimulating factor (Patent Document 1), β-hydroxy-β-methylbutyrate (Patent Document 2), and retinoic acid receptor γ (RARγ) agonist (Patent Document 3) are examples of compounds that promote skeletal muscle repair. It has been reported.

Lactic acid bacteria are bacteria that produce lactic acid in the process of metabolism, and have been used in various fermented foods for a long time. In recent years, the functionality of lactic acid bacteria has been attracting attention as a probiotic (which brings a beneficial effect to the host by reaching the intestine alive).

So far, no literature has disclosed or suggested a composition for promoting muscle repair containing lactic acid bacteria as an active ingredient.

International Publication 2010/131382 Special table 2016-520050 Special table 2013-536855

An object of the present invention is to provide a novel composition for promoting muscle repair containing lactic acid bacteria as an active ingredient.

In order to solve the above problems, the present inventors have diligently studied and found a lactic acid bacterium having a muscle repair promoting action, and completed the present invention.
That is, the present invention provides a novel composition for promoting muscle repair containing lactic acid bacteria as an active ingredient. The present invention also provides a novel industrially usable lactic acid bacterium strain.
Therefore, the present invention has the following configuration.
(1) A composition for promoting muscle repair containing bacterial cells belonging to Lactobacillus and / or a culture thereof as an active ingredient.
(2) Lactobacillus (Lactobacillus) is Lactobacillus gasseri, Lactobacillus delbrucki Subspices delbrucki (Lactobacillus delbrucli sulbacilli subbsp. The composition for promoting muscle repair according to (1), wherein the composition is one or more selected from (helveticus).
(3) Lactobacillus belonging to Lactobacillus is Lactobacillus gasseri SBT2055 (FERM BP-10953), Lactobacillus delbrucky Subspecies Delbrucky SBT0413 (NITE P-02642), Lactobacillus Reuteri SBT19. , Lactobacillus Helveticas SBT11380 (NITE P-02644), which is one or more of the compositions for promoting muscle repair according to (1).
(4) The composition for promoting muscle repair according to any one of (1) to (3), wherein the bacterial cells and / or the culture thereof are dead bacterial cells.
(5) The composition for promoting muscle repair according to (4), wherein the dead cells are an insoluble fraction of the disrupted cells.
(6) New Lactobacillus Lactobacillus Delbrucky Subspecies Delbrucky SBT0413.
(7) New lactic acid bacterium Lactobacillus reuteri SBT1926.
(8) New lactic acid bacterium Lactobacillus herbeticus SBT11380.

According to the present invention, it is possible to provide a composition for promoting muscle repair containing bacterial cells belonging to Lactobacillus and / or a culture thereof as an active ingredient. Further, according to the present invention, it is possible to provide a novel lactic acid bacterium strain that can be industrially used.

It is a graph which compared the myoblast proliferation rate after 48 hours culture by removing the muscle damage agent from the mouse myoblast after the muscle damage agent reaction (24 hours), adding various lactic acid bacteria heated cells. After the muscle-damaging agent reaction (24 hours), the muscle-damaging agent was removed from the mouse myoblasts, and lactic acid bacteria-heated cells (Lactobacillus gasseri) were added at different concentrations to increase the growth rate of myoblasts after culturing for 48 hours. It is a comparison graph. After the muscle-damaging agent reaction (24 hours), the muscle-damaging agent was removed from the mouse myoblasts, a fraction of crushed lactic acid bacteria-heated cells (Lactobacillus gasseri) was added, and the myoblasts were cultured for 48 hours. It is a graph which compared the growth rate.

(Lactic acid bacteria belonging to the genus Lactobacillus)
The lactic acid bacterium belonging to the genus Lactobacillus of the present invention can be any lactic acid bacterium classified into the genus Lactobacillus.
Specifically, Lactobacillus gasseri, Lactobacillus delbrucky subspecies delbrucky (Lactobacillus delbrueckii subsp. Delbrueckii), Lactobacillus reuctiles It is not limited to these.
The lactic acid bacterium belonging to the genus Lactobacillus of the present invention is a lactic acid bacterium belonging to the genus Lactobacillus. , Lactobacillus Reuteri SBT1926 (NITE P-02643), Lactobacillus Helveticas SBT11380 (NITE P-02644) are preferred.
(Preparation of lactic acid bacteria belonging to the genus Lactobacillus)
Lactobacillus belonging to the genus Lactobacillus may be cultured according to a conventional method for culturing lactic acid bacteria to prepare a desired amount. One aspect of the preparation is shown below. Lactic acid bacteria belonging to the genus Lactobacillus are cultured using an MRS (DIFCO) medium, and the obtained culture is collected by centrifugation to obtain bacterial cells. The obtained bacterial cells may be used as they are, or the bacterial cells subjected to concentration, drying, and freeze-drying treatment may be used. As the bacterial cells, those that have been killed by heating and drying can also be used.
(Insoluble fraction of lactic acid bacteria belonging to the genus Lactobacillus (sediment))
An aspect of the method for preparing an insoluble fraction (sediment) of a lactic acid bacterium belonging to the genus Lactobacillus of the present invention is shown below. The lyophilized powder of Lactobacillus cells is suspended in a buffer solution and heated at 80 ° C. for about 30 minutes to obtain heated cells. The heated cells are crushed by a French press. The crushed solution is centrifuged to remove the supernatant to obtain a sediment of lactic acid bacteria belonging to the genus Lactobacillus.
In the composition for promoting muscle repair of the present invention, the active ingredient can be an insoluble fraction of the cell disrupted product, and more specifically, an insoluble fraction of the cell disrupted product in a buffer solution (for example, a phosphate buffer solution). Can be minutes. The soluble fraction of the cell disruption may or may not be additionally included.
(New lactic acid bacterium strain)
The present invention relates to a novel lactic acid bacterium strain. These lactic acid bacteria strains are Lactobacillus delbrucky subspecies delbrucky (Lactobacillus delbruecchii subsp. Delbruecchii) SBT0413 (NITE P-02642), Lactobacillus reuteri (Lactobacillus de lactobacillus) Lactobacillus herveticus SBT11380 (NITE P-02644). Hereinafter, the lactic acid bacterium strain may be referred to as "lactic acid bacterium of the present invention", "lactic acid bacterium strain of the present invention", or simply SBT0413, SBT1926, SBT11380 strain.
These lactic acid strains were sent to SBT0413 on March 15, 2018 at the National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (Postal code 292-0818, Room 2-5-8 122, Kazusakamatari, Kisarazu City, Chiba Prefecture). Is deposited with NITE P-02642, SBT1926 with NITE P-02643, and SBT11380 with NITE P-02644.
The lactic acid bacterium of the present invention is not limited to the above-mentioned lactic acid bacterium strain, and may be a lactic acid bacterium strain substantially equivalent to these deposited lactic acid bacterium strains. A substantially equivalent lactic acid bacterium strain is a lactic acid bacterium strain belonging to Lactobacillus delbrucky Subspecies Delbrucky, Lactobacillus reuteri, and Lactobacillus herbeticus, and has a high muscle repair promoting effect similar to that of the deposited lactic acid bacterium strain. Say.
Further, the substantially equivalent lactic acid bacterium strain has a 16S rRNA gene base sequence of 98% or more, preferably 99% or more, more preferably 100%, which is 98% or more, preferably 99% or more, more preferably 100% or more of the base sequence of the 16S rRNA gene of the deposited lactic acid bacterium strain. It has homology and preferably has the same mycological properties as the above deposited lactic acid strain. Further, the lactic acid bacterium of the present invention was bred from a deposited lactic acid bacterium strain or a lactic acid bacterium strain substantially equivalent thereto by mutation treatment, gene recombination, selection of a natural mutant strain, etc., as long as the effect of the present invention is not impaired. It may be a lactic acid bacterium strain.
(How to Use)
As described above, since the composition of the present invention can also contain cells subjected to concentration, drying, freeze-drying treatment, killed cells obtained by heat-drying, etc. as active ingredients, it is a raw material for preparations, foods and drinks, and feeds. Can be widely used as.
The administration target of the composition of the present invention is not particularly limited and can be administered to humans, but the administration target may be animals other than humans (for example, dogs, cats, horses, rabbits, etc.). When the administration target is a human, it can be administered to minors under 20 years old, adults, elderly people over 65 years old, and the like.
The ingestion amount of the composition of the present invention is individually determined in consideration of the symptom, age, etc. of the administration subject, but in the case of an adult, it may be 0.5-5000 mg and 0.5-500 mg. Is desirable, and 0.5-50 mg is most desirable.
(Evaluation method of muscle repair promoting effect)
Evaluation is possible by the method described in the examples. That is, the evaluation can be performed by the following method.
10 mg / ml Lactobacillus gasseri SBT2055 Heated cells are crushed 3 times with a French press (Aminco) at 1,200 psiG. After crushing, centrifuge (4 ° C., 7000 rpm, 15 minutes) to obtain supernatant and sediment. Further, the supernatant was filtered through a 0.22 μm filter. For the sediment, the same amount of PBS (−) as the removed supernatant is added, and after vortexing, centrifugation (4 ° C., 7000 rpm, 15 minutes) is performed to remove the supernatant. This is repeated 3 times, and the supernatant to which the same amount of PBS (-) is added is used as the sediment. The concentrations of the crushed product supernatant and the sediment obtained from the 10 mg / ml Lactobacillus gasseri SBT2055 heated cells subjected to the French press are set to the equivalent amounts of 10 mg / ml, respectively. Dilute with DMEM (SIGMA) containing 10% FBS (GIBCO) and 1% penicillin streptomycin (SIGMA) to an amount equivalent to 100 μg / ml, and prepare a suspension of crushed supernatant or a suspension of sediment. obtain. C2C12 mouse myoblasts were seeded on a collagen-coated 96-well plate at a rate of 5,000 cells / well _{, and after culturing in a 5% CO 2} incubator at 37 ° C. for 24 hours, 0.5 μM bupivacaine hydrochloride (Wako Pure Chemical Industries, Ltd.) was added to 24. React for time. Then, bupivacaine is removed, uncrushed heated cells, crushed product supernatant, or crushed product sediment is added, and myoblasts are cultured for 48 hours. After culturing, washing with sterile PBS (−) is performed twice, and then cell counting kit-8 (Dojin Kagaku) is added and reacted at 37 ° C. for 2 hours to measure the absorbance at 450 nm. The growth rate is calculated by applying the obtained absorbance value to the formula of (heated bacterial cells-blank) / (heated bacterial cells non-added-blank) × 100. It can be judged that the effect of promoting the growth of myoblasts by the lactic acid bacteria cells promoted the growth of the myoblasts after the injury if an increase in the growth rate was observed as compared with the case where the heated cells were not added.

Hereinafter, the present invention will be described in more detail based on the examples of the present invention, but the present invention is not construed as being limited to such examples. Unless otherwise specified,% indicates weight% in the present specification.

<Example product 1> Heated lactic acid bacteria cells Each of the test bacteria in (1) below was inoculated into MRS medium (DIFCO) and statically cultured at 37 ° C. for 16 hours. After centrifuging the culture (4 ° C., 7000 rpm, 15 minutes), washing with sterile water and centrifugation were repeated 3 times to obtain washed cells. The washed cells were freeze-dried to obtain a cell powder. The cell powder was diluted with sterile PBS (−) to 10 mg / ml and heated at 80 ° C. for 30 minutes to obtain heated cells. Heated cells were diluted with DMEM (SIGMA) containing 10% FBS (GIBCO) and 1% penicillin-streptomycin (SIGMA) to 100 μg / ml.
(1) Test Bacteria The following 7 strains of the genus Lactobacillus were used as test bacteria.
Lactobacillus gasseri (Lactobacillus gasseri) SBT2055 (FERM BP-10953), Lactobacillus del Burukki subsp. Bulgaricus (Lactobacillus delbrueckii subsp. Bulgaricus) SBT2115, Lactobacillus del Burukki subsp del Burukki (Lactobacillus delbrueckii subsp. Delbrueckii) SBT0413 (NITE P-02642), Lactobacillus delbruckii subsp. Lactis SBT2080, Lactobacillus reuteri (Lactobacillus reuteri) SBT1926 (NITE , Lactobacillus brevis SBT2035
FERM BP-10953 has been deposited at the Patent Microorganisms Depositary Center of the National Institute of Advanced Industrial Science and Technology.
<Test Example 1> Screening of lactic acid bacteria that promote muscle repair Example Product 1 was subjected to the following test.
(1) Test method C2C12 mouse myoblasts were cultured in DMEM (SIGMA) containing 10% FBS (GIBCO) and 1% penicillin-streptomycin (SIGMA). C2C12 mouse myoblasts were seeded on a collagen-coated 96-well plate at a rate of 5,000 cells / well _{, and after culturing in a 5% CO 2} incubator at 37 ° C. for 24 hours, 0.5 μM bupivacaine hydrochloride (Wako Pure Chemical Industries, Ltd.) was added to 24. Reacted for time.
Then, bupivacaine was removed, each heated cell was added, and myoblasts were cultured for 48 hours. After culturing, the cells were washed twice with sterile PBS (−), cell counting kit-8 (Dojin Kagaku) was added, and the mixture was reacted at 37 ° C. for 2 hours to measure the absorbance at 450 nm. The growth rate was calculated by applying the obtained absorbance value to the formula of (heated cell addition-blank) / (heated cell non-addition-blank) × 100. It can be judged that the effect of promoting the growth of myoblasts by the lactic acid bacteria cells promoted the growth of the myoblasts after the injury if an increase in the growth rate was observed as compared with the case where the heated cells were not added.

(2) Test results The proliferation rate of myoblasts for each lactic acid bacterium strain is shown in FIG. As a result of measuring the absorbance, an increase in the proliferation rate of myoblasts was observed in the heated cells of 4 out of 7 strains. Therefore, the effect of promoting the proliferation of myoblasts after damage was observed in the heated cells of lactic acid bacteria of a specific strain.

<Test Example 2> Lactobacillus gasseri SBT2055 Concentration-dependent effect of heated cells (preparation of lactic acid bacteria cells)
For Example product 1, the concentration-dependent muscle repair promoting effect of the bacterial cells was investigated.
(1) Test method 10 mg / ml Lactobacillus gasseri SBT2055 Heated cells were mixed with DMEM (SIGMA) containing 10% FBS (GIBCO) and 1% penicillin streptomycin (SIGMA) so as to be 1, 10, 100 μg / ml. Diluted. C2C12 mouse myoblasts were seeded on a collagen-coated 96-well plate at a rate of 5,000 cells / well, and cultured in a 5% CO ₂ incubator at 37 ° C. for 24 hours, followed by 0.5 μM bupivacaine hydrochloride (Wako Pure Chemical Industries, Ltd.) for 24 hours. It was reacted. Then, bupivacaine was removed, heated cells at each concentration were added, and myoblasts were cultured for 48 hours. After culturing, the cells were washed twice with sterile PBS (−), cell counting kit-8 (Dojin Kagaku) was added, and the mixture was reacted at 37 ° C. for 2 hours to measure the absorbance at 450 nm. The growth rate was calculated by applying the obtained absorbance value to the formula of (heated bacterial cells-blank) / (heated bacterial cells non-added-blank) × 100. It can be judged that the effect of promoting the growth of myoblasts by the lactic acid bacteria cells promoted the growth of the myoblasts after the injury if an increase in the growth rate was observed as compared with the case where the heated cells were not added.

(2) Test Results Lactobacillus gasseri SBT2055 The proliferation rate of myoblasts for each heated cell concentration is shown in FIG. As a result of measuring the absorbance, an increase in the proliferation rate of myoblasts was observed depending on the concentration of the Lactobacillus gasseri SBT2055 heated cells. Therefore, the concentration-dependent effect of Lactobacillus gasseri SBT2055 heated cells was observed in the action of promoting the proliferation of myoblasts after injury.

<Test Example 3> Search for the active ingredient of Lactobacillus gasseri SBT2055 heated cells (preparation of lactic acid bacteria cells)
For Example product 1, the effects of promoting muscle repair of the soluble fraction (supernatant) and the insoluble fraction (sediment) of the cell disruption were examined.
(1) Test method 10 mg / ml Lactobacillus gasseri SBT2055 heated cells were crushed three times with a French press (Aminco) at 1,200 psiG. After crushing, centrifugation (4 ° C., 7000 rpm, 15 minutes) was performed to obtain a supernatant and a sediment. Further, the supernatant was filtered through a 0.22 μm filter. For the sediment, the same amount of PBS (−) as the removed supernatant was added, and after vortexing, centrifugation (4 ° C., 7000 rpm, 15 minutes) was performed to remove the supernatant. This was repeated 3 times, and the supernatant to which the same amount of PBS (−) was added was used as the sediment. The concentrations of the crushed product supernatant and the sediment obtained from the 10 mg / ml Lactobacillus gasseri SBT2055 heated cells subjected to the French press were set to the equivalent amounts of 10 mg / ml, respectively. Dilute with DMEM (SIGMA) containing 10% FBS (GIBCO) and 1% penicillin streptomycin (SIGMA) to an amount equivalent to 100 μg / ml, and prepare a suspension of crushed supernatant or a suspension of sediment. Obtained. C2C12 mouse myoblasts were seeded on a collagen-coated 96-well plate at a rate of 5,000 cells / well _{, and after culturing in a 5% CO 2} incubator at 37 ° C. for 24 hours, 0.5 μM bupivacaine hydrochloride (Wako Pure Chemical Industries, Ltd.) was added to 24. Reacted for time. Then, bupivacaine was removed, uncrushed heated cells, crushed product supernatant, or crushed product sediment was added, and myoblasts were cultured for 48 hours. After culturing, the cells were washed twice with sterile PBS (−), cell counting kit-8 (Dojin Kagaku) was added, and the mixture was reacted at 37 ° C. for 2 hours to measure the absorbance at 450 nm. The growth rate was calculated by applying the obtained absorbance value to the formula of (heated bacterial cells-blank) / (heated bacterial cells non-added-blank) × 100. It can be judged that the effect of promoting the growth of myoblasts by the lactic acid bacteria cells promoted the growth of the myoblasts after the injury if an increase in the growth rate was observed as compared with the case where the heated cells were not added.

(2) Test results The proliferation rate of myoblasts for each fraction is shown in FIG. As a result of measuring the absorbance, the crushed sediment of Lactobacillus gasseri SBT2055 heated cells increased the proliferation rate of myoblasts as in the uncrushed cells. Therefore, the insoluble fraction of Lactobacillus gasseri SBT2055 heated cells was found to have the effect of promoting the proliferation of myoblasts after injury.

<Example product 2> Preparation of lactic acid bacterium culture Lactobacillus gasseri SBT2055 was cultured in MRS liquid medium (DIFCO). Each culture solution in the logarithmic growth phase was inoculated with 1% of 10% reduced skim milk (sterilized at 115 ° C. for 20 minutes) to which 0.3% yeast extract was added to prepare mother culture. To this was added 10% reduced skim milk, and 2.5% was added to a yogurt mix heated at 100 ° C. for 10 minutes to prepare. Fermentation was carried out at 37 ° C., and when the lactic acid acidity reached 0.85, the mixture was cooled to complete the fermentation. The obtained fermented milk was freeze-dried to obtain a powder of Lactobacillus gasseri SBT2055 cell culture. The obtained cell culture was resuspended in phosphate buffer ^{and adjusted to 1 × 10 9} cells / ml.

<Example Product 3> Preparation of Lactobacillus casei cells Lactobacillus gasseri SBT2055 was inoculated into MRS liquid medium (DIFCO) and statically cultured at 37 ° C. for 16 hours. The culture was centrifuged at 4 ° C. and 7000 rpm for 15 minutes, and then washed with sterile water and centrifuged three times to obtain washed cells. The washed cells were freeze-dried to obtain a cell powder.

<Example product 4> Production of tablets 4 parts of defatted milk powder was mixed with 1 part of the bacterial cell powder prepared in Example product 3, and 1 g of this mixed powder was tableted by a conventional method with a tableting machine. Tablets containing 200 mg of cells of Lactobacillus gasseri SBT2055 of the invention were prepared respectively.

<Example product 5> Production of powdered product Lactobacillus gasseri SBT2055 was ingested in 5 L of MRS liquid medium (DIFCO), and then statically cultured at 37 ° C. for 18 hours. After completion of the culture, centrifugation was performed at 7000 rpm for 15 minutes to obtain 1/50 of the concentrated cells of the culture solution. Next, the concentrated cells were mixed in the same amount as a dispersion medium containing 10% by weight of skim milk powder and 1% by weight of monosodium glutamate, adjusted to pH 7, and then freeze-dried. The obtained freeze-dried product was sized with a 60-mesh sieve to produce freeze-dried bacterial powder. In accordance with the provisions of the 13th revised Japanese Pharmacopoeia Manual for Pharmaceuticals, "Powder", add 400 g of lactose (Japanese Pharmacopoeia) and 600 g of potato starch (Japanese Pharmacopoeia) to 1 g of this freeze-dried bacterial powder and mix them uniformly to mix the powder. Obtained.

<Example Product 6> Production of Capsules The raw materials were mixed according to the formulation shown in Table 1, granulated into granules, and then filled with 10 mg each in empty capsules to produce capsules.

<Example product 7> Production of stick-shaped health food To 30 g of the powder of Example product 1, 40 g of an equal amount mixture of vitamin C and citric acid, 100 g of granulated sugar, and 60 g of an equal amount mixture of cornstarch and lactose were added and mixed. The mixture was packed in stick-shaped bags to produce stick health foods.

<Example Product 8> Production of Beverages Raw materials were mixed according to the formulation shown in Table 2, filled in a container, and then heat sterilized to produce a fruit juice beverage.

According to the present invention, it is possible to provide a muscle repair promoter containing a lactic acid bacterium cell belonging to Lactobacillus and / or a lactic acid bacterium culture as an active ingredient.

<Reference to deposited biomaterials>
(1) Lactobacillus gasseri SBT2055
B. Name and address of the depositary institution that deposited the biological material Independent Administrative Institution Product Evaluation Technology Infrastructure Organization Patent Biological Deposit Center 2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan Room 120 (Postal code 292-0818)
Date of deposit of biomaterials to Loy's depository March 27, 1996 February 26, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-10953 assigned to the deposit by the depository agency of Hai
(2) Lactobacillus Delbrucky Subspecies Delbrucky SBT0413
B. Name and address of the depositary institution that deposited the biomaterial Independent Administrative Institution Product Evaluation Technology Infrastructure Organization Patent Microorganisms Depositary Center 2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan Room 122 (Postal code 292-0818)
Date of deposit of biological materials to Loy's depository February 21, 2018 Deposit number NITE P-02642 assigned to the deposit by High's depository (Note that after the original deposit date, the deposit is based on the Budapest Treaty based on the original deposit. The application for transfer to was made on May 27, 2019, and after the completion of the survival confirmation test, a document notifying the receipt number was received. The receipt number is NITE ABP-02642.)
(3) Lactobacillus Reuteri SBT1926
B. Name and address of the depositary institution that deposited the biomaterial Independent Administrative Institution Product Evaluation Technology Infrastructure Organization Patent Microorganisms Deposit Center 2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan Room 122 (Postal code 292-0818)
Date of deposit of biological materials to Loy's depository February 21, 2018 Deposit number NITE P-02643 given to the deposit by High's depository (Note that after the original deposit date, the deposit is based on the Budapest Treaty based on the original deposit. The application for transfer to was made on May 27, 2019, and after the completion of the survival confirmation test, a document notifying the receipt number was received. The receipt number is NITE ABP-02643.)
(4) Lactobacillus Helveticas SBT11380
B. Name and address of the depositary institution that deposited the biomaterial Independent Administrative Institution Product Evaluation Technology Infrastructure Organization Patent Microorganisms Deposit Center 2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan Room 122 (Postal code 292-0818)
Date of deposit of biological materials to Loy's depository February 21, 2018 Deposit number NITE P-02644 assigned to the deposit by High's depository (Note that after the original deposit date, the deposit is based on the Budapest Treaty based on the original deposit. The application for transfer to was made on May 27, 2019, and after the completion of the survival confirmation test, a document notifying the receipt number was received. The receipt number is NITE ABP-02644.)

Claims (8)

A composition for promoting muscle repair containing bacterial cells belonging to Lactobacillus and / or a culture thereof as an active ingredient. Bacteria belonging to the Lactobacillus (Lactobacillus) is, Lactobacillus gasseri (Lactobacillus gasseri), Lactobacillus del Burukki subsp del Burukki (Lactobacillus delbrueckii subsp. Delbrueckii), from Lactobacillus reuteri (Lactobacillus reuteri), Lactobacillus helveticus (Lactobacillus helveticus) The composition for promoting muscle repair according to claim 1, wherein the composition is one or more selected. Lactobacillus belonging to Lactobacillus is Lactobacillus gasseri SBT2055 (FERM BP-10953), Lactobacillus delbrucky Subspecies Delbrucky SBT0413 (NITE P-02642), Lactobacillus reuteri SBT26 The composition for promoting muscle repair according to claim 1, wherein the composition is one or more selected from Helveticas SBT11380 (NITE P-02644). The composition for promoting muscle repair according to any one of claims 1 to 3, wherein the bacterial cells and / or the culture thereof are dead bacterial cells. The composition for promoting muscle repair according to claim 4, wherein the dead cells are an insoluble fraction of the disrupted cells. New Lactobacillus Lactobacillus Delbrucky Subspecies Delbrucky SBT0413. New lactic acid bacterium Lactobacillus reuteri SBT1926. New lactic acid bacterium Lactobacillus herbeticus SBT11380.

Images